glimepiride has been researched along with Non-alcoholic Fatty Liver Disease in 3 studies
glimepiride: structure given in first source
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity." | 7.11 | Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity." | 3.11 | Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it is known that the presence of type 2 diabetes mellitus leads to the aggravation of NAFLD." | 2.94 | Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. ( Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F, 2020) |
| "A total of 95 T2DM and NAFLD patients were randomly divided into group A (saxagliptin group), group B (glimepiride group), and group C (glimepiride combined with polyene phosphatidylcholine group)." | 1.51 | The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. ( Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Takeshita, Y | 1 |
| Honda, M | 1 |
| Harada, K | 1 |
| Kita, Y | 1 |
| Takata, N | 1 |
| Tsujiguchi, H | 1 |
| Tanaka, T | 1 |
| Goto, H | 1 |
| Nakano, Y | 1 |
| Iida, N | 1 |
| Arai, K | 1 |
| Yamashita, T | 1 |
| Mizukoshi, E | 1 |
| Nakamura, H | 1 |
| Kaneko, S | 1 |
| Takamura, T | 1 |
| Kinoshita, T | 1 |
| Shimoda, M | 1 |
| Nakashima, K | 1 |
| Fushimi, Y | 1 |
| Hirata, Y | 1 |
| Tanabe, A | 1 |
| Tatsumi, F | 1 |
| Hirukawa, H | 1 |
| Sanada, J | 1 |
| Kohara, K | 1 |
| Irie, S | 1 |
| Kimura, T | 1 |
| Nakamura, Y | 1 |
| Nishioka, M | 1 |
| Obata, A | 1 |
| Nakanishi, S | 1 |
| Mune, T | 1 |
| Kaku, K | 1 |
| Kaneto, H | 1 |
| Li, JJ | 1 |
| Zhang, P | 1 |
| Fan, B | 1 |
| Guo, XL | 1 |
| Zheng, ZS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver[NCT02649465] | Phase 4 | 40 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for glimepiride and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Inflammation; Liver; | 2022 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fe | 2020 |
1 other study available for glimepiride and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; H | 2019 |